Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4

Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 Uses, Dosage, Side Effects, Food Interaction and all others data.

Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

Table Of contents

• Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4
Generic	Coltuximab ravtansine
Coltuximab ravtansine Other Names	Anti-CD19 humanized monoclonal antibody conjugated to DM4, Coltuximab ravtansine
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in lymphoma (non-hodgkin's).

How Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 works

SAR3419 is an anti-CD19-DM4 immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells. [National Cancer Institute Drug Dictionary]

Innovators Monograph

You find simplified version here Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4